EU regulator backs Bayer, GSK drugs, knocks back Novartis, Teva

[riky]

EU regulator backs Bayer, GSK drugs, knocks back Novartis, Teva

<p><a href="http://news.yahoo.com/eu-regulator-backs-bayer-gsk-drugs-knocks-back-125621233--sector.html"><img src="http://l2.yimg.com/bt/api/res/1.2/zvhm.elANmRMUUKqQXJj5A--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9NzU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2014-01-24T130135Z_1_CBREA0N106Q00_RTROPTP_2_BAYER.JPG" width="130" height="86" alt="A man rides a bicycle in front of the building of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals in Berlin" align="left" title="A man rides a bicycle in front of the building of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals in Berlin" border="0" /></a>By Kate Kelland LONDON (Reuters) - Europe's drugs regulator gave its backing on Friday for marketing approval to be granted for Bayer's pulmonary hypertension drug Adempas and for GlaxoSmithKline's diabetes medicine Eperzan. The European Medicine Agency (EMA) also backed a new drug from Dainippon Sumitomo Pharma called Latuda, for the treatment of schizophrenia, and Bemfola, a new biosimilar medicine for the treatment of infertility. But the regulator decided against recommending Teva's new multiple sclerosis (MS) pill Nerventra, or laquinimod, which the Israeli firm is developing with Swedish partner Active Biotech, and recommended rejecting an application from Swiss drugmaker Novartis to market its heart failure drug serelaxin. Recommendations for marketing approval by the EMA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.</p><br clear="all"/>

Source: You are not allowed to view links. Register or Login